U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...
Eli Lilly partners with Walmart to sell its weight-loss drug Zepbound nationwide, giving patients easier, insurance-free access through LillyDirect.
Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback